- Home
- INM vs BJDX Comparison
INM vs BJDX Comparison
Compare INM & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- BJDX
- Stock Information
- Founded
- INM 1981
- BJDX 2015
- Country
- INM Canada
- BJDX United States
- Employees
- INM N/A
- BJDX N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- INM Health Care
- BJDX Health Care
- Exchange
- INM Nasdaq
- BJDX Nasdaq
- Market Cap
- INM 3.2M
- BJDX 2.9M
- IPO Year
- INM N/A
- BJDX 2021
- Fundamental
- Price
- INM $2.75
- BJDX $1.58
- Analyst Decision
- INM
- BJDX
- Analyst Count
- INM 0
- BJDX 0
- Target Price
- INM N/A
- BJDX N/A
- AVG Volume (30 Days)
- INM 5.7M
- BJDX 50.7K
- Earning Date
- INM 05-12-2025
- BJDX 08-13-2025
- Dividend Yield
- INM N/A
- BJDX N/A
- EPS Growth
- INM N/A
- BJDX N/A
- EPS
- INM N/A
- BJDX N/A
- Revenue
- INM $4,920,990.00
- BJDX N/A
- Revenue This Year
- INM N/A
- BJDX N/A
- Revenue Next Year
- INM N/A
- BJDX $55.56
- P/E Ratio
- INM N/A
- BJDX N/A
- Revenue Growth
- INM N/A
- BJDX N/A
- 52 Week Low
- INM $1.72
- BJDX $1.46
- 52 Week High
- INM $15.70
- BJDX $37.50
- Technical
- Relative Strength Index (RSI)
- INM 46.31
- BJDX 43.21
- Support Level
- INM $2.66
- BJDX $1.60
- Resistance Level
- INM $2.97
- BJDX $1.69
- Average True Range (ATR)
- INM 0.37
- BJDX 0.07
- MACD
- INM -0.05
- BJDX 0.01
- Stochastic Oscillator
- INM 15.12
- BJDX 30.00
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.